Pharmafile Logo
Pharmafocus logo
Advanced Search

Novo Nordisk

Showing 15 posts of 180 posts found.

novo_corp_hq2

Novo Nordisk’s diabetes drug “significantly reduced’ cardiovascular risk

September 16, 2016
Medical Communications Novo Nordisk, diabetes, semaglutide

Novo Nordisk has announced that its diabetes drug semaglutide “significantly reduced” the risk of major cardiovascular events at the 52nd …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 9, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis

It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …

News

Lars Rebien Sørensen to retire as CEO of Novo Nordisk

September 1, 2016
Novo Nordisk, appointment

Novo Nordisk has announced that its president and CEO Lars Rebian Sørensen (pictured) is to retire at the end of …

News

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016
Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …

News
novo_flag

Novo Nordisk says its insulin pump secures EMA marketing authorisation

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing EMA, Novo Nordisk, insulin pump, marketing, product launch

Diabetes drugmaker Novo Nordisk (NYSE: NYO) said it has secured European Medicines Agency (EMA) marketing approval for its insulin pump.  …

News
novo_flag

Novo Nordisk says Victoza lowers risk of heart attacks in diabetes patients

June 14, 2016
Manufacturing and Production, Research and Development Novo Nordisk, Victoza, drug trial, type 2 diabetes

Danish diabetes drugmaker giant Novo Nordisk (NYSE: NVO) on Tuesday said a large study showed its Victoza (liraglutide) reduced the risk of …

News
novo_flag

Novo Nordisk presents Tresiba data showing significantly lower hypoglycaemia rates

June 13, 2016
Research and Development, Sales and Marketing Novo Nordisk, Tresiba

Novo Nordisk (CPH: NOVO-B) has presented new Phase IIIb data on Tresiba (insulin degludec) at the American Diabetes Association annual …

News
novo_flag

Novo Nordisk presents positive long-term results for Saxenda

June 3, 2016
Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss

Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …

News
novo_flag

FDA committee unanimously recommends Novo Nordisk diabetes combo, IDegLira

May 25, 2016
Research and Development, Sales and Marketing FDA, Novo Nordisk, Panel, Tresiba, Victoza, committee, ideglira, recommendation, staff

Novo Nordisk has announced that a US Food and Drug Administration (FDA) advisory committee has unanimously recommended IDegLira, a type-2 …

News
novo_nordisk_flag

Novo Nordisk Q1 operating profit down 10% in local currencies

April 29, 2016
Medical Communications, Sales and Marketing Financial, Novo Nordisk, Q1, earnings, outlook, results

Denmark’s Novo Nordisk (NYSE: NOV) on Friday posted a 10% drop in first-quarter operating profit and said it maintains its full year …

News
novo_corp_hq2

Novo unveils new research grant to mark World Haemophilia Day

April 18, 2016
Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day

Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …

News
novo_flag

Novo says Victoza bests MSD’s Januvia at lowering blood sugar

April 4, 2016
Research and Development Novo Nordisk, Victoza

Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – …

News
novo_flag

Novo Nordisk breaks ground on new $2 billion production facility in North Carolina

March 29, 2016
Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility

Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …

News
novo_nordisk

Novo Nordisk reports five-year Victoza cardiovascular safety data

March 7, 2016
Research and Development, Sales and Marketing Novo Nordisk, Victoza

Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …

News
novo_nordisk

Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment

March 2, 2016
Sales and Marketing Novo Nordisk, Xultophy, diabetes

Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …

News

Latest content

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024